Experimental drug tested for rare, stubborn cancers in kids and adults
NCT ID NCT03165721
Summary
This study tested whether a drug called SGI-110 could shrink or slow the growth of certain rare cancers that don't respond well to standard treatments. It was for people aged 12 and older with specific types of gastrointestinal, adrenal, or kidney cancers that had progressed despite other therapies. Participants received daily injections of the drug for 5 days in repeating monthly cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.